Avalon GloboCare Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avalon GloboCare Corp. (NASDAQ: ALBT) develops and commercializes precision diagnostics, cellular therapies, and clinical laboratory services within the biotechnology and healthcare sectors. The company offers clinical laboratory testing including general bloodwork, anatomic pathology, urine toxicology, and pharmacogenomics; precision diagnostic consumer products such as the KetoAir breathalyzer for real-time ketosis monitoring via nanosensor technology; immune effector cell therapies encompassing AVA-001, AVA-011, FLASH-CAR, ACTEX, and AVA-Trap programs; exosome technologies; the QTY protein design platform developed jointly with Massachusetts Institute of Technology; and strategic advisory, outsourcing, and healthcare consulting services. Avalon GloboCare operates primarily in the United States with affiliated hospital networks focused on hematology, oncology, cellular immunotherapy, and regenerative medicine; it also pursues international expansion including a UK commercial launch of KetoAir breathalyzer nanosensor technology in September 2025. Founded in 2014 and headquartered in Freehold, New Jersey, the company manages two reportable segments comprising real property operations and medical-related consulting services; it went public in 2016 and uplisted to Nasdaq in 2018. Recent developments include a definitive merger agreement announced in March 2025 with YOOV Group Holding Limited, a business AI automation provider that reported 59.1% annual revenue growth to $45.7 million in 2024, expected to close in Q3 2025 with Phil Wong assuming CEO role; a February 2023 acquisition of 40% membership interest in Laboratory Services MSO, LLC to bolster laboratory capabilities; and a partnership with Qi Diagnostics announced in 2025 to co-develop a real-time cannabis breathalyzer for impaired driving detection.
Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition
Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now
Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform
Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews
Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments
Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Avalon GloboCare expands its cellular immuno-oncology program with addition of Chimeric Antigen Receptor-Natural Killer cell therapies
Avalon GloboCare well poised for growth this year; intended SenlangBio acquisition terminated
Avalon GloboCare advances its AI-enhanced protein design technology for cellular therapy development in collaboration with MIT
Avalon GloboCare successfully co-develops novel platform of S-layer coated emulsome technology for next-generation drug delivery and cellular immunotherapy
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
Avalon GloboCare announces co-development of in-silico system to expand its ability to design and produce novel cell membrane proteins
Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment
AVALON GLOBOCARE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Avalon GloboCare Corp. - AVCO